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Abstract
Background: Over 4.2 million confirmed cases and more than 285,000 deaths, COVID-19 pandemic continues to
harm significant number of people worldwide. Several studies have reported the impact of COVID-19 in general
population; however, there is scarcity of information related to pharmacological management and maternal and
perinatal outcomes during the pandemic. Altered physiological, anatomical, and immunological response during
pregnancy makes it more susceptible to infections. Furthermore, during pregnancy, a woman undergoes multiple
interactions with the health care system that increases her chance of getting infected; therefore, managing
pregnant population presents a unique challenge.
Research questions: This systematic review seeks to answer the following questions in relation to COVID-19:
 What are the different clinical characteristics presented in maternal and perinatal population?
 What are the different maternal and perinatal outcome measures reported?
 What are the distinct therapeutic interventions reported to treat COVID-19?
 Is it safe to use “medications” used in the treatment of COVID-19 during antenatal, perinatal, postnatal, and
breastfeeding?
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Method: The search will follow a comprehensive, sequential three step search strategy. Several databases relevant to
COVID-19 and its impact on pregnancy including Medline, CINAHL, and LitCovid will be searched from the inception of the
disease until the completion of data collection. The quality of this search strategy will be assessed using Peer Review of
Electronic Search Strategies Evidence-Based Checklist (PRESS EBC). An eligibility form will be developed for a transparent
screening and inclusion/exclusion of studies. All studies will be sent to RefWorks, and abstraction will be independently
performed by two researchers. Risk of bias will be assessed using Cochrane Risk of Bias tool for randomized controlled trials,
Newcastle–Ottawa Quality Assessment Scale for non-randomized studies, and for case reports, Murad et al. tool will be used.
Decision to conduct meta-analysis will be based on several factors including homogeneity and outcome measures reported;
otherwise, a narrative synthesis will be deemed appropriate.
Discussion: This systematic review will summarize the existing data on effect of COVID-19 on maternal and
perinatal population. Furthermore, to the best of our knowledge, this is the first systematic review addressing
therapeutic management and safety of medicines to treat COVID-19 during pregnancy and breastfeeding.
Systematic review registration: This systematic review has been registered and published with Prospero
(CRD42020172773).
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Background
The novel coronavirus now known as SARS-CoV-2 (se-
vere acute respiratory syndrome coronavirus 2) has
spread globally [1]. On 12 March 2020, the World
Health Organization (WHO) declared it as a “pandemic”
outbreak of utmost international concern [2, 3]. The first
coronavirus patient was identified in Wuhan City, China,
in December 2019 [4, 5]. Previous infectious outbreaks,
such as, H1N1 influenza virus, Zika virus, severe acute
respiratory syndrome corona virus (SARS-CoV), and
Middle East respiratory syndrome corona virus (MERS
CoV), have had significant impact on maternal as well as
perinatal outcomes [6, 7].
Epidemiology, transmission, and symptoms
Ever since the first case reported in China, the infection
has been spreading at an accelerating pace, across 213
countries, infecting over 3.7 million people, 261,380
cases of death (as of 5 May, 2020), at an estimated case
fatality ranging 0.5–6% [3]. Adults and older people are
more susceptible to the infection in comparison to youn-
ger age group, while the infection is predominantly re-
ported among men, the rate of infection among children
is scarce [8, 9]. Furthermore, co-morbidities such as dia-
betes, hypertension, cardiovascular, or respiratory disor-
ders are significantly associated with poor outcomes and
substantially increased mortality rate [10, 11].
While vast majority of cases are categorized as “mild”
or “uncomplicated,” almost 14% of patients require
hospitalization and/or oxygen support, and approxi-
mately 5% required intensive care admission to survive
[12]. Common clinical manifestations reported among
hospitalized patients were fever (83–100%), cough (59–
82%), myalgia (11–35%), headache (7–8%), and diarrhea
(2–10%). Almost all patients had abnormal radiographic
chest imaging [5, 13, 14].
The National Institutes of Health (NIH) in the USA has
since developed a tool to categorize the severity of the dis-
ease, based on the presenting symptoms (Table 1).
The transmission routes of COVID-19 include direct
transmission, droplet inhalation transmission, and con-
tact transmission [15].
COVID-19 and its impact on pregnancy
The “obstetric” population is considered vulnerable as
different stages of pregnancy involve multiple interac-
tions with the health care system; therefore, managing
pregnant population presents a unique challenge during
this pandemic. Additionally, the physiological changes
and partial immune suppression during pregnancy
makes pregnant women and newborn babies susceptible
to several infections. Post-partum hemorrhage, maternal
sepsis, preeclampsia, and premature rupture of mem-
brane are the most common COVID-19-induced adverse
events reported among pregnant women [16].
Anecdotal evidence suggests that pregnant women do
not appear to be different than the general population in
terms of disease transmission, and to date, there is no
evidence of vertical transmission from mother to fetus.
There are currently limited data on first trimester or
early pregnancy COVID-19 infections. One case from
Iran reported poor maternal outcomes at 30-week gesta-
tion causing maternal and fetal death [17]. Data from
the Intensive Care National Audit and Research Centre
in the UK reported a marginal difference in the rate of
current/recent pregnancy among all individuals admitted
to critical care (2.3%) compared to the reported rate for
non-COVID viral pneumonia during 2017–19 (3.3%). In
one study, 47% (15/32) of pregnant women with
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COVID-19 infections delivered preterm; another study
reported 7/15 women delivered preterm by Cesarean
section [17]. Cesarean section is the most commonly re-
ported mode of delivery for patients confirmed with
COVID-19 [17]. Several studies have shown no detri-
mental effect on the fetal growth where COVID-19 posi-
tive pregnant women deliver within 13 days after the
onset of symptoms [18–21].
Another study followed 13 pregnant women diagnosed
with COVID19, mostly in their third trimester (11 pa-
tients < 28 weeks gestation). Three were discharged and
continued to their pregnancy; however, eight underwent
cesarean section due to reasons including fetal distress
(3), premature rupture of the membrane or PROM (1),
stillbirth (1), multiple organ dysfunction (1), and 6 cases
delivered preterm [18]. While in the state of pregnancy,
reduced mobility and hospital admissions are considered
as risk factors for hypercoagulable disorders; COVID-19
infection during pregnancy is more likely to cause ma-
ternal venous-thromboembolism [16].
To date, there is no valid evidence suggesting COVID-
19 infection in the amniotic fluid, umbilical cord blood,
or breastmilk samples.
COVID-19 and its impact on perinatal and breastfeeding
While there is scarcity of evidence demonstrating effect
of COVID-19 on the fetus, factors such as mother-to-
child vertical transmission and its long-term and short-
term effect on the offspring remain unclear. Wang et al.
reported a case with positive qRT-PCR in both the
mother and the neonate. The mother was admitted at
40 weeks gestation, and computerized tomography (CT)
images were remarkable, suggesting for COVID-19; fol-
lowing which, she underwent emergency cesarean sec-
tion delivering the baby with normal Apgar scores.
Hours after birth, the neonate had lymphocytopenia, de-
ranged liver function, elevated creatine kinase, and a
pharyngeal swab collected 36 h after birth turned posi-
tive [20].
Pharmacological management of pregnant women with
COVID-19
Ever since the outbreak, the healthcare team and re-
searchers across the globe have proposed several
pharmacological interventions that could prove effective
in treating COVID-19 [22]. Various treatment options
include, but are not limited to, antivirals and combina-
tions, angiotensin receptor blockers, antimalarial, anti-
histamines, steroids, and antipyretics [23]. While
COVID-19 treatment strategies vary across different
countries, the WHO and the Centers for Disease Con-
trol and Prevention (CDC) guidelines are very general,
and both advise to manage pregnant and pediatric pa-
tients with caution.
Rationale for this review
Infecting over 4 million people, the global pandemic is
anticipated to affect considerable number of pregnant
women worldwide. The alarmingly increasing mortality
rates warrant an early identification and protection of
this vulnerable population. Despite favorable maternal
and perinatal outcomes reported in most cases, the sci-
entific evidence in managing this vulnerable population
remains unclear [24]. There is a scarcity of evidence
demonstrating pharmacological management and mater-
nal and perinatal outcomes during COVID-19.
The existing studies have predominantly originated
from one geographical location, or as single case or case
series. Furthermore, fewer sample size, varied findings,
and continuously evolving treatment protocols and am-
biguity in reliability of these results make the findings
difficult to interpret. Hence, collating scientific evidence
concerning the pandemic is imperative. Therefore, a sys-
tematic review evaluating the maternal and perinatal
outcomes and therapeutic management of pregnant
women diagnosed with COVID-19 is highly
recommended.
Research questions
This systematic review seeks to answer the following
questions in relation to COVID-19:
 What are the different clinical characteristics
presented in maternal and perinatal population?
 What are the different maternal and perinatal
outcome measures reported?
 What are the distinct therapeutic interventions
reported to treat COVID-19?
 Is it safe to use “medications” used in the treatment
of COVID-19 during antenatal, perinatal, postnatal,
and breastfeeding?
Table 1 NIH COVID-19 severity assessment scale
Severity Symptoms
Asymptomatic Positive test for SARS-CoV-2 but no symptoms
Mild illness Any signs and symptoms (e.g., fever, cough, sore throat,
malaise, headache, muscle pain) without shortness of
breath, dyspnea, or abnormal chest imaging.
Moderate
illness
Evidence of lower respiratory disease by clinical
assessment or imaging and a saturation of oxygen
(SaO2) > 93% on room air at sea level.
Severe illness Respiratory frequency > 30 breaths per minute, SaO2 ≤
93% on room air at sea level, ratio of arterial partial
pressure of oxygen to fraction of inspired oxygen
(PaO2/FiO2) < 300, or lung infiltrates > 50%.
Critical illness Respiratory failure, septic shock, and/or multiple organ
dysfunction.
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Methods/design
Study registration
This systematic review was registered on the Inter-
national Prospective Register of Systematic Reviews
(PROSPERO) (CRD42020181163) on the 23rd of April
2020 [25] (Additional file 1). This protocol is prepared
in accordance with the Preferred Reporting Item for Sys-
tematic Review and Meta-analysis (PRISMA-P) state-
ment [26] (Additional file 2); the PROSPERO record will
be updated simultaneously in case of any important
amendments.
Eligibility criteria
Inclusion
Type of studies Study designs, particularly case reports,
case series, observational studies, randomized and quasi-
randomized controlled trials (RCTs/CCTs), controlled
before and after studies (CBAs), and interrupted time
series (ITSs), will be included. Previous systematic re-
views will be analyzed for cross-referencing. Only studies
published in English will be included in this review.
Type of participants The current review will include all
studies reporting clinical characteristics, outcomes, treat-
ment options, and any reported adverse events, in preg-
nant women diagnosed with COVID-19 and/or the
fetuses and infants of mothers who are COVID-19 posi-
tive. Infants and children exposed in utero during deliv-
ery or breastfeeding will be included. There will be no
restriction with respect to age, ethnicity, setting, or
location.
Type of exposure Pregnant women infected and diag-
nosed (laboratory-confirmed infection) with COVID-19
infection (exposure) will be considered as an
intervention.
Type of comparators We do not anticipate any RCTs
for pregnant women diagnosed with COVID-19; how-
ever, if any, uninfected pregnant women will be the
comparator/control.
Outcome measures
Outcome 1 (clinical characteristics)
Clinical characteristics as illustrated by the NIH defin-
ition will be classified as mild, moderate, and severe. See
Table 1.
Outcome 2 (maternal and perinatal outcomes)
The maternal mortality and morbidity; other complica-
tions such as post-partum hemorrhage, maternal sepsis,
and preeclampsia; mode of delivery; PPROM; ventilator
support; or ICU. Perinatal outcomes, APGAR scores,
neonatal birth outcomes, birth weight, infections, IUGR,
and mortality.
Outcome 3 (safety of therapeutic interventions)
The primary outcome in terms of safety of the medica-
tions used in the treatment of COVID-19 in pregnancy,
post-pregnancy, and breastfeeding is presence of malfor-
mation, still birth, or child death. Secondary outcome in-
cludes drug interactions, drug disease interactions, any
adverse drug reactions, other minor adverse drug events,
or medication errors reported due to the pharmaco-
logical agents used in the treatment of COVID-19 infec-
tions among pregnant women.
Exclusion
Studies that do not report/present a laboratory-
confirmed infection will be excluded. Studies published
in any other language other than English will be ex-
cluded. Studies reporting COVID-19 infections in non-
pregnant or women with gynecological complications
will excluded from the review. Data obtained from nar-
rative reviews, abstracts, personal opinions, commentar-
ies, and conference presentations will be excluded. Also,
studies published before 12 December 2019 will be
excluded.
Databases and search strategy
Literature search
The search will be developed by DS and BT and will fol-
low a comprehensive, sequential three step search strat-
egy. Both DS and BT have substantial experience in
systematic reviews and developing search strategies. The
quality of this search strategy will be assessed by at least
two independent researchers using the Peer Review of
Electronic Search Strategies Evidence-Based Checklist
(PRESS EBC) [27].
The first step will be an initial limited search that will
include two most relevant online databases (MEDLINE/
PubMed and CINAHL); we will identify the key words
in the title and abstract of retrieved papers and the index
terms used to describe the articles.
In the second search, we will use all identified key-
words and index terms to search across different data-
bases. All search terms used for the search will be added
in the appendix. Various Boolean operators (AND/OR/
NOT), truncation, wildcards, etc. either individually or
in combination will be used to ensure the comprehen-
siveness of the search process.
The electronic databases that will be searched are as
follows:
1. MEDLINE®
2. PubMed®
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3. The Cumulative Index of Nursing and Allied Health
Literature (CINAHL®)
4. LitCovid
5. ScienceDirect
6. The Cochrane Database of Systematic Reviews
(CDSR)
7. The Centre for Reviews and Dissemination (CRD)
8. Joanna Briggs Institute Library (JBI)
Thirdly, the reference list of identified, relevant articles
will be searched for additional studies. In case of missing
information/incomplete data, the authors of primary
studies will be contacted.
All studies published in English from the inception of
this disease (December 2019) until the completion of
this review will be included. References will be managed
using RefWorks.
Study selection
A study eligibility form will be developed for screening
the titles, abstracts, and potentially relevant full-text arti-
cles. The form will be developed by BT and DS and
shared across the team; the form will be tested and re-
vised if necessary. Inter-rater reliability will be calculated
from the pilot-test, and screening will only commence
after high agreement (e.g., kappa statistic ≥ 60%) is ob-
served. All the articles will be individually screened by 2
authors, BT/DS; any disagreements will be clarified by
contacting a third reviewer (PAR). The studies will be
classified into three categories: (1) included, (2) ex-
cluded, and (3) pending. Pending articles will be consid-
ered as those articles that initially appear to
incompletely fit the exclusion and/or the inclusion cri-
teria. A decision to include or exclude the pending arti-
cles will be made through discussion and mutual
consensus. All screening procedures will be presented
using a PRISMA flow diagram.
Data extraction
All studies identified will be sent to RefWorks and the
duplicated will be removed. Data abstraction will be per-
formed by two independent reviewers (BT and PAR)
using a standardized template to independently apply
the inclusion and exclusion criteria, any disagreements
will be resolved by discussion between the two, or else a
third reviewer (FAH) will be contacted if no consensus
is reached. The extraction will include four main
categories:
(i) General characteristics of the reviewed studies such
as country, month/year of publication, study
objective(s), study design, period of study, and type
of hospital, number of beds, and number of patients
(ii) Maternal outcomes: number of patients, age, parity,
pregnancy outcome, ethnicity, presence of
comorbidities, and any other pregnancy-related
complications, maternal mortality, and other
outcome-related data
Perinatal outcomes: gestational age, neonatal com-
promise (APGAR scores), neonatal birth outcomes, birth
weight, infections, mal-presentation, intrauterine growth
restriction and mortality, the study will also include data
on vertical transmission if available.
(iii)Pharmacological interventions: drug name,
pharmacological class, dose, route, frequency,
concurrent medications used, etc.
(iv) Safety of medications used: if any reported drug
interactions, adverse drug reactions, adverse drug
events, or any other complications due to
pharmacological agents used
Assessment of risk of bias
In order to achieve a consistency in assessing the risk of
bias, the review team will pre-assess a sample of selected
studies, and the result of the assessment will be shared
among the assessors as well as the review team and dis-
cussed. Pairs of reviewers will independently assess qual-
ity of each of the studies (BT and PAR). The Cochrane
Risk of Bias tool [28] will be used for randomized con-
trolled trials (if any), and for non-randomized studies in-
cluding retrospective cohort, cohort before and after
studies, case control studies, we plan to use the Newcas-
tle–Ottawa Quality Assessment Scale (NOS) [29]. NOS
is a three-dimensional appraisal tool to assess the meth-
odological quality that includes (i) selected population,
(ii) comparability of groups, and (iii) outcome of interest.
Considering scarcity of information around this topic,
no studies will be excluded based on the assessment of
risk of bias. The study team will also consider Murad
et al. tool for assessing quality of case reports and case
series [30].
Data synthesis and analysis
If the studies are found heterogeneous, a narrative syn-
thesis method will be considered as appropriate, all in-
cluded studies will be summarized in the form of a
detailed commentary in accordance to the data extrac-
tion form summarized in the previous section. Tables
and graphs will be created to illustrate the key study
characteristics such as population characteristics, mater-
nal or perinatal outcomes, sample sizes, settings, medica-
tions used, results, and any other important aspect
related to each research question of interest. Descriptive
analysis will be performed for all categorical variables
using frequency, mean, and standard deviation wherever
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possible. If the studies are found similar enough to be
pooled, a random effect meta-analysis will be applied.
We will consider clinical, methodological, and statistical
aspects to determine the heterogeneity among the stud-
ies. Variance in the clinical interventions and outcomes
studied among the studies will be described as clinically
heterogeneous. Methodological heterogeneity will be
taken into account if the studies vary in study design or
risk of bias. Any variations in the interventions being
evaluated will be considered as statistically heteroge-
neous. Statistical heterogeneity between studies will be
assessed using τ2 and I2 statistics, and P < 0.10 and I2 >
than 50% will be considered as a high level of statistical
heterogeneity between the studies.
Quality of evidence
Two authors will independently assess the quality of evi-
dence for each outcome. The quality of evidence will be
determined by Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) system
[31]. The studies will be rated based on their evidence
ranging high, moderate, low, or very low level. Individual
outcomes will be assessed for the following aspects, limi-
tations, inconsistency, indirectness, imprecision, and
publication bias.
Discussion
As pandemic continues to affect a large number of preg-
nant women worldwide, the findings of this systematic
review will contribute to improve to the current state of
knowledge about effect of COVID-19 on maternal and
perinatal population. Furthermore, to the best of our
knowledge, this is the first systematic review addressing
therapeutic management and safety of medicines to treat
COVID-19 during pregnancy and breastfeeding.
Pooling of data for meta-analysis seems difficult as we
anticipate a considerable degree of heterogeneity between
the studies in terms of study design, exposure measure-
ment, characteristics of participants, and outcomes.
To ensure a wider dissemination, we will present the
interim findings at local and international conferences
and publish the findings in high impact open access
journals. Furthermore, we will brief the findings to key
stakeholders, policymakers, antimicrobial stewardship
committee, hospital infection control committee, etc.
Strengths and limitations of this study
 To the best of our knowledge, this will be the first
review to use a validated systematic and transparent
methodological process to appraise and summarize
the existing literature on COVID-19-associated
pregnancy and perinatal outcomes.
 To the best of our knowledge, this systematic review
is the first to address the pharmacological
management in COVID-19 and its impact on mater-
nal and perinatal outcomes.
 The proposed systematic review is in accordance to
the Preferred Reporting Items for Systematic
Reviews and Meta Analyses guidelines (PRISMA),
ensuring consistency and uniformity in reporting the
full systematic review.
 Two independent reviewers will screen the eligible
studies and perform extraction and quality
assessment to minimize potential reviewer bias.
 One key limitation of this review is it will only
include studies published in English, while majority
of cases were reported from China, and there are
chances that we may miss information published in
Chinese or other regional languages. This limitation
may cause bias.
 There is a possibility of reporting bias, as we plan to
exclude no studies based on the quality, and there is
a possibility that findings originate from low and
inconsistent studies.
This systematic review is anticipated to summarize the
available evidence that examined the impact of COVID
19 infections in maternal and perinatal outcomes. Fi-
nally, the results will be most likely to be used to provide
recommendations to the current topic of concern and
provide endorsements to future research.
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